Endothelin antagonism and its role in the treatment of hypertension

Current Hypertension Reports

Volumn 15, Issue 5, 2013, Pages 489-496

  Moorhouse, Rebecca C ^a   Webb, David J ^a   Kluth, David C ^b   Dhaun, Neeraj ^a,b  

^a UNIVERSITY OF EDINBURGH   (United Kingdom)

^b UNIVERSITY OF EDINBURGH   (United Kingdom)

Author keywords

Blood pressure; BP; Chronic kidney disease; CKD; Endothelin 1; ET 1; Hypertension; Metabolic syndrome; Primary hypertension; Resistant hypertension

Indexed keywords

AMBRISENTAN; AMINOTRANSFERASE; BOSENTAN; DARUSENTAN; ENDOTHELIN; ENDOTHELIN 1; ENDOTHELIN 2; ENDOTHELIN 3; ENDOTHELIN A RECEPTOR; ENDOTHELIN B RECEPTOR; ENDOTHELIN CONVERTING ENZYME; ENDOTHELIN RECEPTOR ANTAGONIST;

AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; BINDING AFFINITY; DISEASE ASSOCIATION; DRUG ANTAGONISM; DRUG RECEPTOR BINDING; DRUG SAFETY; FLUID RETENTION; HEADACHE; HUMAN; HYPERTENSION; HYPERTRANSAMINASEMIA; LIVER TOXICITY; METABOLIC SYNDROME X; NONHUMAN; PERIPHERAL EDEMA; RECEPTOR DENSITY; RESISTANT HYPERTENSION; UNSPECIFIED SIDE EFFECT;

ANIMALS; ANTIHYPERTENSIVE AGENTS; BLOOD PRESSURE; ENDOTHELIN-1; HUMANS; HYPERTENSION; RECEPTORS, ENDOTHELIN; RENAL INSUFFICIENCY, CHRONIC;

EID: 84893638697     PISSN: 15226417     EISSN: 15343111     Source Type: Journal    
DOI: 10.1007/s11906-013-0380-1     Document Type: Article

References (67)

1. Lim SS, Vos T, Flaxman AD, et al. A comparative risk assessment of burden of disease and injury attributable to 67 risk factors and risk factor clusters in 21 regions, 1990-2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet. 2012;380:2224-60.
2. Myat A, Redwood SR, Qureshi AC, et al. Resistant hypertension. Br Med J. 2012;345:7.
3. Foster MC, Rawlings AM, Marrett E, et al. Cardiovascular risk factor burden, treatment, and control among adults with chronic kidney disease in the United States. Am Heart J. 2013. doi:10.1016/j.ahj.2013. 03.016.
4. Mendizabal Y, Llorens S, Nava E. Hypertension in metabolic syndrome: vascular pathophysiology. Int J Hyper. 2013. doi:10.1155/2013/230868.
5. Yanagisawa M, Kurihara H, Kimura S, et al. A novel potent vasoconstrictor peptide produced by vascular endothelial-cells. Nature. 1988;332:411-5.
6. Inoue A, Yanagisawa M, Kimura S et al. The human endothelin family - 3 structurally and pharmacologically distinct isopeptides predicted by 3 separate genes. PNAS 1989, 86.
7. Haynes WG, Webb DJ. Contribution of endogenous generation of endothelin-1 to basal vascular tone. Lancet. 1994;344:852-4.
8. Komuro I, Kurihara H, Sugiyama T, et al. Endothelin stimulates c-fos and c-myc expression and proliferation of vascular smooth-muscle cells. FEBS Lett. 1988;238:249-52.
9. Dawes KE, Cambrey AD, Campa JS, et al. Changes in collagen metabolism in response to endothelin-1: Evidence for fibroblast heterogeneity. Int J Biochem Cell Biol. 1996;28:229-38.
10. Halcox J P J, Nour K R A, Zalos G, Quyyumi AA. Coronary vasodilation and improvement in endothelial dysfunction with endothelin ETA receptor blockade. Circ Res. 2001;89:969-76.
11. Vuurmans T J L, Boer P, Koomans HA. Effects of endothelin-1 and endothelin-1 receptor blockade on cardiac output, aortic pressure, and pulse wave velocity in humans. Hypertension. 2003;41:1253-8.
12. Shohet RV, Kisanuki YY, Zhao XS, et al. Mice with cardiomyocytespecific disruption of the endothelin-1 gene are resistant to hyperthyroid cardiac hypertrophy. PNAS. 2004;101:2088-93.
13. Attina T, Camidge R, Newby DE, Webb DJ. Endothelin antagonism in pulmonary hypertension, heart failure, and beyond. Heart. 2005;91:825-31.
14. Wagner OF, Christ G, Wojta J, et al. Polar secretion of endothelin-1 by cultured endothelial-cells. J Biol Chem. 1992;267:16066-8.
15. Arai H, Hori S, Aramori I et al. Cloning and expression of a cDNAencoding an endothelin receptor. Nature 1990, 348.
16. Sakamoto A, Yanagisawa M, Sakurai T et al. Cloning and functional expression of human cDNA for the ETB endothelin receptor. Biochem Biophys Res Comm 1991, 178.
17. Davenport AP, Oreilly G, Kuc RE. Endothelin ETA and ETB messenger-rna and receptors expressed by smooth-muscle in the human vasculature - majority of the ETA sub-type. Br J Pharmacol. 1995;114:1110-6.
18. Karet FE, Kuc RE, Davenport AP. Novel ligands BQ123 and BQ3020 characterize endothelin receptor subtypes ETA and ETB in human kidney. Kidney Int. 1993;44:36-42.
19. Herrera M, Garvin JL. Endothelin stimulates endothelial nitric oxide synthase expression in the thick ascending limb. Am J Physiol. 2004;287:F231-5.
20. Johnstrom P, Fryer TD, Richards HK, et al. Positron emission tomography using F-18-labelled endothelin-1 reveals prevention of binding to cardiac receptors owing to tissue-specific clearance by ETB receptors in vivo. Br J Pharmacol. 2005;144:115-22.
21. Maguire JJ, Kuc RE, Davenport AP. Defining the affinity and receptor sub-type selectivity of four classes of endothelin antagonists in clinically relevant human cardiovascular tissues. Life Sci. 2012;91:681-6.
22. Goddard J, Webb DJ. Endothelin antagonists and hypertension: A question of dose? Hypertension. 2002;40:E1-2.
23. Schiffrin EL. Vascular endothelin in hypertension. Vasc Pharmacol 2005, 43.
24. Mortensen LH, Pawloski CM, Kanagy NL, Fink GD. Chronic hypertension produced by infusion of endothelin in rats. Hypertension. 1990;15:729-33.
25. Pollock DM, Pollock JS. Evidence for endothelin involvement in the response to high salt. Am J Physiol. 2001;281:F144-50.
26. Mortensen LH, Fink GD. Salt-dependency of endothelin-induced, chronic hypertension in conscious rats. Hypertension. 1992;19:549-54.
27. Moreau P. Endothelin in hypertension: A role for receptor antagonists? Cardiovasc Res. 1998;39:534-42.
28. Saito Y, Nakao K, Mukoyama M, Imura H. Increased plasma endothelin level in patients with essential-hypertension. New Engl J Med 1990, 322.
29. Cody RJ, Haas GJ, Binkley PF et al. Plasma endothelin correlates with the extent of pulmonary-hypertension in patients with chronic congestive-heart- failure. Circulation 1992, 85.
30. Davenport AP, Ashby MJ, Easton P, et al. A sensitive radioimmunoassay measuring endothelin-like immunoreactivity in human plasma - comparison of levels in patients with essential-hypertension and normotensive control subjects. Clin Sci. 1990;78:261-4.
31. Schiffrin EL, Thibault G. Plasma endothelin in human essentialhypertension. Am J Hyper. 1991;4:303-8.
32. Fukuroda T, Fujikawa T, Ozaki S et al. Clearance of circulating endothelin-1 by ETB receptors in rats. Biochem Biophys Res Commun 1994, 199.
33. Cardillo C, Kilcoyne CM, Waclawiw M, et al. Role of endothelin in the increased vascular tone of patients with essential hypertension. Hypertension. 1999;33:753-8.
34. Martin P, Ninio D, Krum H. Effect of endothelin blockade on basal and stimulated forearm blood flow in patients with essential hypertension. Hypertension. 2002;39:821-4.
35. Krum H, Viskoper RJ, Lacourciere Y, et al. The effect of an endothelinreceptor antagonist, bosentan, on blood pressure in patients with essential hypertension. New Engl J Med. 1998;338:784-90.
36. Rohmeiss P, Birck R, Braun C, et al. Pharmacology of the endothelin A receptor antagonist: LU 135252. Cardiovasc Drug Rev. 1998;16:391-412.
37. Nakov R, Pfarr E, Eberle S, Investigators H. Darusentan: An effective endothelin A receptor antagonist for treatment of hypertension. Am J Hyper. 2002;15:583-9.
38. Black HR, Bakris GL, Weber MA, et al. Efficacy and safety of darusentan in patients with resistant hypertension: results from a randomized, double-blind, placebo-controlled dose-ranging study. J Clin Hyper. 2007;9:760-9.
39. Weber MA, Black H, Bakris G, et al. A selective endothelin-receptor antagonist to reduce blood pressure in patients with treatmentresistant hypertension: a randomised, double-blind, placebocontrolled trial. Lancet. 2009;374:1423-31.
40. Bakris GL, Lindholm LH, Black HR, et al. Divergent results using clinic and ambulatory blood pressures report of a darusentan-resistant hypertension trial. Hypertension. 2010;56:824-30. A large clincal trial where the decrease in BP with an ETAR selective antagonist was similar to placebo. This result terminated any future studies.
41. Webb DJ. DORADO: opportunity postponed lessons from studies of endothelin receptor antagonists in treatment-resistant hypertension. Hypertension. 2010;56:806-7.
42. Ruggenenti P, Schieppati A, Remuzzi G. Progression, remission, regression of chronic renal diseases. Lancet. 2001;357:1601-8.
43. Vaneckova I, Kramer HJ, Backer A, et al. Early endothelin-A receptor blockade decreases blood pressure and ameliorates end-organ damage in homozygous Ren-2 rats. Hypertension. 2005;46:969-74.
44. Koyama H, Nishzawa Y, Morii H, et al. Plasma endothelin levels in patients with uremia. Lancet. 1989;1:991-2.
45. Goddard J, Johnston NR, Cumming AD, Webb DJ. Fractional urinary excretion of endothelin-1 is reduced by acute ETB receptor blockade. Am J Physiol. 2007;293:F1433-8.
46. Orisio S, Benigni A, Bruzzi I, et al. Renal endothelin gene-expression is increased in remnant kidney and correlates with disease progression. Kidney Int. 1993;43:354-8.
47. Goddard J, Johnston NR, Hand MF, et al. Endothelin-A receptor antagonism reduces blood pressure and increases renal blood flow in hypertensive patients with chronic renal failure - A comparison of selective and combined endothelin receptor blockade. Circulation. 2004;109:1186-93.
48. Dhaun N, MacIntyre IM, Melville V, et al. Blood pressureindependent reduction in proteinuria and arterial stiffness after acute endothelin-A receptor antagonism in chronic kidney disease. Hypertension. 2009;54:U113-U71.
49. Wu CD, Chan MF, Stavros F, et al. Discovery of TBC11251, a potent, long acting, orally active endothelin receptor-A selective antagonist. J Med Chem. 1997;40:1690-7.
50. Dhaun N, MacIntyre IM, Kerr D, et al. Selective endothelin-A receptor antagonism reduces proteinuria, blood pressure, and arterial stiffness in chronic proteinuric kidney disease. Hypertension. 2011;57:772. Reduction in blood pressure and cardiovascular risk factors with chronic ETAR selective antagonism in CKD.
51. Sarafidis PA, Bakris GL. Review: Insulin and endothelin: An interplay contributing to hypertension development? J Clin Endocrin Metabol. 2007;92:379-85.
52. Formoso G, Chen H, Kim JA, et al. Dehydroepiandrosterone mimics acute actions of insulin to stimulate production of both nitric oxide and endothelin 1 via distinct phosphatidylinositol 3-kinase- and mitogen-activated protein kinase-dependent pathways in vascular endothelium. Mol Endocrinol. 2006;20:1153-63.
53. Van Harmelen V, Eriksson A, Astrom G, et al. Vascular peptide endothelin-1 links fat accumulation with alterations of visceral adipocyte lipolysis. Diabetes. 2008;57:378-86.
54. Wolpert HA, Steen SN, Istfan NW, Simonson DC. Insulin modulates circulating endothelin-1 levels in humans. Metabolism. 1993;42:1027-30.
55. Juan CC, Shen YW, Chien Y, et al. Insulin infusion induces endothelin-1-dependent hypertension in rats. Am J Physiol. 2004;287:E948-54.
56. Cardillo C, Campia U, Bryant MB, Panza JA. Increased activity of endogenous endothelin in patients with type II diabetes mellitus. Circulation. 2002;106:1783-7.
57. Shemyakin A, Bohm F, Wagner H, et al. Enhanced endotheliumdependent vasodilatation by dual endothelin receptor blockade in individuals with insulin resistance. J Cardiovasc Pharmacol. 2006;47:385-90.
58. Amiri F, Virdis A, Neves MF, et al. Endothelium-restricted overexpression of human endothelin-1 causes vascular remodeling and endothelial dysfunction. Circulation. 2004;110:2233-40.
59. Saleh MA, Boesen EI, Pollock JS, et al. Endothelin-1 increases glomerular permeability and inflammation independent of blood pressure in the rat. Hypertension. 2010;56:U942-427.
60. Barton M, Haudenschild CC, D'Uscio LV, et al. Endothelin ETA receptor blockade restores NO-mediated endothelial function and inhibits atherosclerosis in apolipoprotein E-deficient mice. PNAS. 1998;95:14367-72.
61. Teerlink JR, Loffler BM, Hess P, et al. Role of endothelin in the maintenance of blood-pressure in conscious rats with chronic heartfailure-acute effects of the endothelin receptor antagonist RO-47-0203 (bosentan). Circulation. 1994;90:2510-8.
62. Humbert M, Segal ES, Kiely DG, et al. Results of european postmarketing surveillance of bosentan in pulmonary hypertension. Eur Resp J. 2007;30:338-44.
63. Ben-Yehuda O, Pizzuti D, Brown A, et al. Long-term hepatic safety of ambrisentan in patients with pulmonary arterial hypertension. J Am Coll Cardiol. 2012;60:80-1.
64. Barst RJ, Langleben D, Frost A, et al. Sitaxsentan therapy for pulmonary arterial hypertension. Am J Resp Crit Care Med. 2004;169:441-7.
65. Kohan D, Strait K, Stricklett P et al. Identification of the site of endothelin a receptor antagonist-induced fluid retention. Hypertension 2011, 58:E155-E.
66. Liu X, He L, Dinger B, et al. Effect of endothelin receptor antagonist bosentan on chronic hypoxia-induced inflammation and chemoafferent neuron adaptation in rat carotid body. HighAltMed Biol. 2012;13:209-16.
67. Clozel M, Breu V, Gray GA, et al. Pharmacological characterization of bosentan, a new potent orally-active nonpeptide endothelin receptor antagonist. J Pharmaocl Exp Ther. 1994;270:228-35.